A Study of MEDI9197 in Participants with Solid Tumors or CTCL and in Combination with Durvalumab and/or Palliative Radiation in Participants with Solid Tumors

Trial Identifier: D6410C00001
Sponsor: MedImmune, LLC
NCTID:: NCT02556463
Start Date: November 2015
Primary Completion Date: October 2018
Study Completion Date: October 2018
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
French Translation
French Translation

Trial Locations

Country Location
Canada, ON Toronto, ON, Canada, M5G 1Z6
France Rennes Cedex 9, France, 35033
France Villejuif Cedex, France, 94805
South Korea Seoul, South Korea, 03080
South Korea Seoul, South Korea, 06351
Spain Barcelona, Spain, 08035
Spain Majadahonda, Spain, 28222
Spain Pamplona, Spain, 31008
United States of America, CA San Francisco, CA, United States of America, 94115
United States of America, CO Aurora, CO, United States of America, 80045
United States of America, FL Tampa, FL, United States of America, 33612
United States of America, MA Boston, MA, United States of America, 02215
United States of America, MN Minneapolis, MN, United States of America, 55455
United States of America, MO St Louis, MO, United States of America, 63110
United States of America, NC Chapel Hill, NC, United States of America, 27599-7305
United States of America, NY New York, NY, United States of America, 10029
United States of America, PA Philadelphia, PA, United States of America, 19104
United States of America, TX Houston, TX, United States of America, 77030